Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
September 24, 2024
Over the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. Takeda Oncology │ Leadership │ Article
If you are a journalist or member of the media looking for Takeda Oncology resources, visit the media materials section of our newsroom.
For other Takeda news releases, please visit the Takeda.com Newsroom.
For media inquiries or reporter requests for more information, contact Oncology Communications via [email protected]. If you generally would like to contact us, please visit Contact Us.